Relmada Therapeutics

Neumora Therapeutics' navacaprant, a KOR antagonist for major depressive disorder, failed its first Phase III trial, missing primary and secondary endpoints. Despite safety, its efficacy was inconsistent, especially in gender responses. Neumora awaits results from two more Phase III trials, amidst skepticism from analysts.

Relmada Therapeutics discontinues Reliance II and Relight Phase 3 studies following DMC evaluation, exploring strategic alternatives to maximize shareholder value, and continuing Phase 1 study of REL-P11 for metabolic disease.

CRISPR Therapeutics' stock has declined 46% since its 52-week high, despite FDA approval of Casgevy for sickle cell disease and beta thalassemia. Analysts suggest patient uptake has been slower than expected, partly due to treatment alternatives and high cost. ARK Investment Management has increased its stake in CRISPR Therapeutics, believing in the long-term value of gene editing cures. Despite recent dips, ARK funds have sold off shares, reflecting broader investor sentiment. Casgevy's commercial progress is seen as positive, with 45 of 75 treatment centers activated and initial revenue generated.

Relmada Therapeutics announced the Reliance II Phase 3 study is futile, unlikely to meet primary efficacy endpoint. No new safety signals reported. CEO Sergio Traversa expresses disappointment and plans to evaluate next steps for REL-1017 program.

Relmada Therapeutics' shares plummet 70% after interim analysis of Phase 3 Reliance II trial shows it unlikely to meet primary efficacy endpoint for MDD treatment with REL-1017.

Relmada Therapeutics' stock dropped 75% after the DMC deemed the Phase 3 Reliance II study of REL-1017 for MDD futile. CEO Sergio Traversa plans to evaluate the dataset for next steps. Despite this, Relmada remains committed to developing REL-P11 for metabolic disease and holds $54.1 million in cash.

Relmada Therapeutics announced the DMC found Reliance II Phase 3 study futile for REL-1017 in MDD, with no new safety concerns. Relmada will evaluate next steps for REL-1017 and focus on REL-P11 for metabolic disease. The company is well-capitalized with $54.1 million in cash.